The peroxisome proliferators are hepatocyte mitogens in chemically-defined media: glucocorticoid-induced PPAR alpha is linked to peroxisome proliferator mitogenesis.
Peroxisome proliferator-induced mitogenesis is believed to play a role in hepatocarcinogenesis, but it has not been possible to demonstrate high level induction of DNA synthesis by peroxisome proliferators in cultured hepatocytes. We now show that four structurally dissimilar peroxisome proliferators (methylclofenapate, Wy-14 643, tetradecyl-3-thia acetic acid and clofibrate) cause high level induction of DNA synthesis in primary cultures of rat hepatocytes, routinely 7-9 fold above control, with up to 29% of cells undergoing S-phase. Peroxisome proliferators induce DNA synthesis rapidly, with maximal response 24 h after dosing [compared with 48 h for epidermal growth factor (EGF)]; indeed, peroxisome proliferators were mitogenic in a chemically defined medium, i.e. with no added exogenous growth factors. EGF-treated hepatocytes that had undergone DNA synthesis comprised 23% binucleated cells, whereas hepatocytes induced into S-phase by peroxisome proliferators contained only 3% binucleated cells, demonstrating a distinct response of hepatocytes to peroxisome proliferators and EGF. The presence of a glucocorticoid was essential for peroxisome proliferator-induced DNA synthesis, but not for EGF-induced DNA synthesis, demonstrating that the requirement for glucocorticoids is selective for peroxisome proliferators. Hydrocortisone was shown to induce the expression of peroxisome proliferator activated receptor-alpha (PPAR alpha), and we propose that it is the glucocorticoid-induced expression of PPAR alpha that is essential for peroxisome proliferator mitogenesis. This in vitro system provides a powerful tool for investigating the mechanism and role of peroxisome proliferator-induced mitogenesis in liver growth and carcinogenesis.
Plant
N J
NJ
Department of Life Science, University of Nottingham, UK.
Horley
N J
NJ
Savory
R L
RL
Elcombe
C R
CR
Gray
T J
TJ
Bell
D R
DR
D000818:Animals; D002992:Clofenapate / Q000494:pharmacology; D002994:Clofibrate / Q000494:pharmacology; D004261:DNA Replication / Q000187:drug effects; D005938:Glucocorticoids / Q000494:pharmacology*; D006133:Growth Substances / Q000494:pharmacology; D008099:Liver / Q000187:drug effects*; D008297:Male; D008830:Microbodies / Q000187:drug effects*; D008934:Mitogens / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D018160:Receptors, Cytoplasmic and Nuclear / Q000096:biosynthesis*; D013440:Sulfides / Q000494:pharmacology; D014157:Transcription Factors / Q000096:biosynthesis*
D005938:Glucocorticoids; D006133:Growth Substances; D008934:Mitogens; D011743:Pyrimidines; D018160:Receptors, Cytoplasmic and Nuclear; D013440:Sulfides; D014157:Transcription Factors; D002992:Clofenapate; C062078:1-(carboxymethylthio)tetradecane; C006253:pirinixic acid; D002994:Clofibrate